Imaging and target volume delineation in Glioma

Clinical Oncology

Volumn 26, Issue 7, 2014, Pages 364-376

  Whitfield, G A ^a   Kennedy, S R ^a   Djoukhadar, I K ^b   Jackson, A ^b  

^a CHRISTIE HOSPITAL   (United Kingdom)

^b UNIVERSITY OF MANCHESTER   (United Kingdom)

Author keywords

Amino acid PET; Glioma; Imaging biomarkers; Molecular resonance imaging; Radiotherapy planning; Target volume delineation

Indexed keywords

FLUOROETHYLTYROSINE F 18; METHIONINE C 11; RADIOPHARMACEUTICAL AGENT; UNCLASSIFIED DRUG;

ARTICLE; BRAIN CORTEX; CANCER GRADING; CANCER RADIOTHERAPY; CANCER SURVIVAL; CELL PROLIFERATION; CLINICAL PRACTICE; CONTRAST ENHANCEMENT; DIFFUSION TENSOR IMAGING; DIFFUSION WEIGHTED IMAGING; DISEASE FREE SURVIVAL; DOSIMETRY; FUNCTIONAL NEUROIMAGING; GLIOMA; HUMAN; IMAGE ANALYSIS; MOLECULAR IMAGING; NUCLEAR MAGNETIC RESONANCE IMAGING; OVERALL SURVIVAL; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; TREATMENT PLANNING; TUMOR INVASION; TUMOR MICROENVIRONMENT; WHITE MATTER; BRAIN NEOPLASMS; PROCEDURES; RADIOTHERAPY PLANNING SYSTEM;

BRAIN NEOPLASMS; GLIOMA; HUMANS; RADIOTHERAPY PLANNING, COMPUTER-ASSISTED;

EID: 84902108985     PISSN: 09366555     EISSN: 14332981     Source Type: Journal    
DOI: 10.1016/j.clon.2014.04.026     Document Type: Article

References (71)

1. Cancer Research UK. Brain, other CNS and intracranial tumours incidence statistics. Available at:. [accessed 27.10.13]. http://www.cancerresearchuk.org/cancer-info/cancerstats/types/brain/incidence/.
2. Stupp R., Hegi M.E., Mason W.P., et al. Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial. Lancet Oncol 2009, 10(5):459-466.
3. Stupp R., Mason W.P., van den Bent M.J., et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. NEngl J Med 2005, 352(10):987-996.
4. Cairncross G., Wang M., Shaw E., et al. Phase III trial of chemoradiotherapy for anaplastic oligodendroglioma: long-term results of RTOG 9402. JClin Oncol 2013, 31(3):337-343.
5. van den Bent M.J., Brandes A.A., Taphoorn M.J., et al. Adjuvant procarbazine, lomustine, and vincristine chemotherapy in newly diagnosed anaplastic oligodendroglioma: long-term follow-up of EORTC brain tumor group study 26951. JClin Oncol 2013, 31(3):344-350.
6. European Organisation for Research and Treatment of Cancer. EORTC protocol 26053 - 22054. Phase III trial on concurrent and adjuvant temozolomide chemotherapy in non-1p/19qdeleted anaplastic glioma. The CATNON intergroup trial. Available at:. [accessed 10.11.13]. http://www.eortc.be/protoc/details.asp?protocol=26053.
7. Karim A.B., Maat B., Hatlevoll R., et al. Arandomized trial on dose-response in radiation therapy of low-grade cerebral glioma: European Organization for Research and Treatment of Cancer (EORTC) Study 22844. Int J Radiat Oncol Biol Phys 1996, 36(3):549-556.
8. Shaw E., Arusell R., Scheithauer B., et al. Prospective randomized trial of low- versus high-dose radiation therapy in adults with supratentorial low-grade glioma: initial report of a North Central Cancer Treatment Group/Radiation Therapy Oncology Group/Eastern Cooperative Oncology Group study. JClin Oncol 2002, 20(9):2267-2276.
9. van den Bent M.J., Afra D., de Witte O., et al. Long-term efficacy of early versus delayed radiotherapy for low-grade astrocytoma and oligodendroglioma in adults: the EORTC 22845 randomised trial. Lancet 2005, 366(9490):985-990.
10. Whittle I.R. The dilemma of low grade glioma. JNeurol Neurosurg Psychiatry 2004, 75(Suppl. 2):ii31-ii36.
11. International Commission on Radiation Units and Measurement ICRU Report 50: Prescribing, recording and reporting photon beam therapy 1993, ICRU, Bethesda, MD.
12. Radiation Therapy Oncology Group. Phase III double-blind placebo-controlled trial of conventional concurrent chemoradiation and adjuvant temozolomide plus bevacizumab versus conventional concurrent chemoradiation and adjuvant temozolomide in patients with newly diagnosed glioblastoma. Available at:. [accessed 27.10.13]. http://www.rtog.org/ClinicalTrials/ProtocolTable/StudyDetails.aspx?study=0825.
13. Fairchild A., Weber D.C., Bar-Deroma R., et al. Quality assurance in the EORTC 22033-26033/CE5 phase III randomized trial for low grade glioma: the digital individual case review. Radiother Oncol 2012, 103(3):287-292.
14. Shaw E.G., Wang M., Coons S.W., et al. Randomized trial of radiation therapy plus procarbazine, lomustine, and vincristine chemotherapy for supratentorial adult low-grade glioma: initial results of RTOG 9802. JClin Oncol 2012, 30(25):3065-3070.
15. Hochberg F.H., Pruitt A. Assumptions in the radiotherapy of glioblastoma. Neurology 1980, 30(9):907-911.
16. Oppitz U., Maessen D., Zunterer H., Richter S., Flentje M. 3D-recurrence-patterns of glioblastomas after CT-planned postoperative irradiation. Radiother Oncol 1999, 53(1):53-57.
17. Wallner K.E., Galicich J.H., Krol G., Arbit E., Malkin M.G. Patterns of failure following treatment for glioblastoma multiforme and anaplastic astrocytoma. Int J Radiat Oncol Biol Phys 1989, 16(6):1405-1409.
18. Burger P.C., Dubois P.J., Schold S.C., et al. Computerized tomographic and pathologic studies of the untreated, quiescent, and recurrent glioblastoma multiforme. JNeurosurg 1983, 58(2):159-169.
19. Halperin E.C., Bentel G., Heinz E.R., Burger P.C. Radiation therapy treatment planning in supratentorial glioblastoma multiforme: an analysis based on post mortem topographic anatomy with CT correlations. Int J Radiat Oncol Biol Phys 1989, 17(6):1347-1350.
20. Farace P., Giri M.G., Meliado G., et al. Clinical target volume delineation in glioblastomas: pre-operative versus post-operative/pre-radiotherapy MRI. Br J Radiol 2011, 84(999):271-278.
21. Minniti G., Amelio D., Amichetti M., et al. Patterns of failure and comparison of different target volume delineations in patients with glioblastoma treated with conformal radiotherapy plus concomitant and adjuvant temozolomide. Radiother Oncol 2010, 97(3):377-381.
22. Wick W., Stupp R., Beule A.C., et al. Anovel tool to analyze MRI recurrence patterns in glioblastoma. Neuro Oncol 2008, 10(6):1019-1024.
23. Dobelbower M.C., Burnett O.L., Nordal R.A., et al. Patterns of failure for glioblastoma multiforme following concurrent radiation and temozolomide. JMed Imaging Radiat Oncol 2011, 55(1):77-81.
24. McDonald M.W., Shu H.K., Curran W.J., Crocker I.R. Pattern of failure after limited margin radiotherapy and temozolomide for glioblastoma. Int J Radiat Oncol Biol Phys 2011, 79(1):130-136.
25. Paulsson A.K., McMullen K.P., Peiffer A.M., et al. Limited margins using modern radiotherapy techniques does not increase marginal failure rate of glioblastoma. Am J Clin Oncol 2014, 37(2):177-181.
26. Creak A.L., Tree A., Saran F. Radiotherapy planning in high-grade gliomas: a survey of current UK practice. Clin Oncol (RColl Radiol) 2011, 23(3):189-198.
27. Ghose A., Lim G., Husain S. Treatment for glioblastoma multiforme: current guidelines and Canadian practice. Curr Oncol 2010, 17(6):52-58.
28. Burnet N.G., Lynch A.G., Jefferies S.J., et al. High grade glioma: imaging combined with pathological grade defines management and predicts prognosis. Radiother Oncol 2007, 85(3):371-378.
29. Douw L., Klein M., Fagel S.S., et al. Cognitive and radiological effects of radiotherapy in patients with low-grade glioma: long-term follow-up. Lancet Neurol 2009, 8(9):810-818.
30. Klein M., Heimans J.J., Aaronson N.K., et al. Effect of radiotherapy and other treatment-related factors on mid-term to long-term cognitive sequelae in low-grade gliomas: a comparative study. Lancet 2002, 360(9343):1361-1368.
31. de Groot J.F., Yung W.K. Bevacizumab and irinotecan in the treatment of recurrent malignant gliomas. Cancer J 2008, 14(5):279-285.
32. Stadlbauer A., Ganslandt O., Buslei R., et al. Gliomas: histopathologic evaluation of changes in directionality and magnitude of water diffusion at diffusion-tensor MR imaging. Radiology 2006, 240(3):803-810.
33. Price S.J., Jena R., Burnet N.G., Carpenter T.A., Pickard J.D., Gillard J.H. Predicting patterns of glioma recurrence using diffusion tensor imaging. Eur Radiol 2007, 17(7):1675-1684.
34. Jena R., Price S.J., Baker C., et al. Diffusion tensor imaging: possible implications for radiotherapy treatment planning of patients with high-grade glioma. Clin Oncol (R Coll Radiol) 2005, 17(8):581-590.
35. Painter K.J., Hillen T. Mathematical modelling of glioma growth: the use of Diffusion Tensor Imaging (DTI) data to predict the anisotropic pathways of cancer invasion. JTheoret Biol 2013, 323:25-39.
36. Wienhard K., Pawlik G., Nebeling B., et al. Estimation of localcerebral glucose utilization by positron emission tomography: comparison of [18F]2-fluoro-2-deoxy-D-glucose and [18F]2-fluoro-2-deoxy-D-mannose in patients with focal brain lesions. JCerebr Blood Flow Metab 1991, 11(3):485-491.
37. Roelcke U., Radu E., Ametamey S., Pellikka R., Steinbrich W., Leenders K.L. Association of rubidium and C-methionine uptake in brain tumors measured by positron emission tomography. JNeurooncol 1996, 27(2):163-171.
38. Chung J.K., Kim Y.K., Kim S.K., et al. Usefulness of 11C-methionine PET in the evaluation of brain lesions that are hypo- or isometabolic on 18F-FDG PET. Eur J Nucl Med Mol Imaging 2002, 29(2):176-182.
39. Sato N., Suzuki M., Kuwata N., et al. Evaluation of the malignancy of glioma using 11C-methionine positron emission tomography and proliferating cell nuclear antigen staining. Neurosurg Rev 1999, 22(4):210-214.
40. Kracht L.W., Friese M., Herholz K., et al. Methyl-[11C]- l-methionine uptake as measured by positron emission tomography correlates to microvessel density in patients with glioma. Eur J Nucl Med Mol Imaging 2003, 30(6):868-873.
41. Okita Y., Kinoshita M., Goto T., et al. (11)C-methionine uptake correlates with tumor cell density rather than with microvessel density in glioma: a stereotactic image-histology comparison. Neuroimage 2010, 49(4):2977-2982.
42. Arita H., Kinoshita M., Kagawa N., et al. (1)(1)C-methionine uptake and intraoperative 5-aminolevulinic acid-induced fluorescence as separate index markers of cell density in glioma: a stereotactic image-histological analysis. Cancer 2012, 118(6):1619-1627.
43. Glaudemans A.W., Enting R.H., Heesters M.A., et al. Value of 11C-methionine PET in imaging brain tumours and metastases. Eur J Nucl Med Mol Imaging 2013, 40(4):615-635.
44. Pirotte B., Goldman S., Dewitte O., et al. Integrated positron emission tomography and magnetic resonance imaging-guided resection of brain tumors: a report of 103 consecutive procedures. JNeurosurg 2006, 104(2):238-253.
45. Voges J., Herholz K., Holzer T., et al. 11C-methionine and 18F-2-fluorodeoxyglucose positron emission tomography: a tool for diagnosis of cerebral glioma and monitoring after brachytherapy with 125I seeds. Stereotactic Functional Neurosurg 1997, 69(1-4 Pt 2):129-135.
46. Lee I.H., Piert M., Gomez-Hassan D., et al. Association of 11C-methionine PET uptake with site of failure after concurrent temozolomide and radiation for primary glioblastoma multiforme. Int J Radiat Oncol Biol Phys 2009, 73(2):479-485.
47. Pauleit D., Floeth F., Hamacher K., et al. O-(2-[18F]fluoroethyl)-L-tyrosine PET combined with MRI improves the diagnostic assessment of cerebral gliomas. Brain 2005, 128(Pt 3):678-687.
48. Piroth M.D., Holy R., Pinkawa M., et al. Prognostic impact of postoperative, pre-irradiation (18)F-fluoroethyl-l-tyrosine uptake in glioblastoma patients treated with radiochemotherapy. Radiother Oncol 2011, 99(2):218-224.
49. Niyazi M., Geisler J., Siefert A., et al. FET-PET for malignant glioma treatment planning. Radiother Oncol 2011, 99(1):44-48.
50. Vees H., Senthamizhchelvan S., Miralbell R., Weber D.C., Ratib O., Zaidi H. Assessment of various strategies for 18F-FET PET-guided delineation of target volumes in high-grade glioma patients. Eur J Nucl Med Mol Imaging 2009, 36(2):182-193.
51. Piroth M.D., Pinkawa M., Holy R., et al. Integrated boost IMRT with FET-PET-adapted local dose escalation in glioblastomas. Results of a prospective phase II study. Strahlenther Onkol 2012, 188(4):334-339.
52. Rieken S., Habermehl D., Giesel F.L., et al. Analysis of FET-PET imaging for target volume definition in patients with gliomas treated with conformal radiotherapy. Radiother Oncol 2013, 109(3):487-492.
53. Kinoshita M., Arita H., Goto T., et al. Anovel PET index, 18F-FDG-11C-methionine uptake decoupling score, reflects glioma cell infiltration. JNucl Med 2012, 53(11):1701-1708.
54. Tie Y., Suarez R.O., Whalen S., Radmanesh A., Norton I.H., Golby A.J. Comparison of blocked and event-related fMRI designs for pre-surgical language mapping. Neuroimage 2009, 47(Suppl. 2):T107-T115.
55. Le Bihan D., Mangin J.F., Poupon C., et al. Diffusion tensor imaging: concepts and applications. JMag Res Imag 2001, 13(4):534-546.
56. Castellano A., Bello L., Michelozzi C., et al. Role of diffusion tensor magnetic resonance tractography in predicting the extent of resection in glioma surgery. Neuro Oncol 2012, 14(2):192-202.
57. Stadlbauer A., Nimsky C., Gruber S., et al. Changes in fiber integrity, diffusivity, and metabolism of the pyramidal tract adjacent to gliomas: a quantitative diffusion tensor fiber tracking and MR spectroscopic imaging study. Am J Neuroradiol 2007, 28(3):462-469.
58. Miller P., Coope D., Thompson G., Jackson A., Herholz K. Quantitative evaluation of white matter tract DTI parameter changes in gliomas using nonlinear registration. Neuroimage 2012, 60(4):2309-2315.
59. Pantelis E., Papadakis N., Verigos K., et al. Integration of functional MRI and white matter tractography in stereotactic radiosurgery clinical practice. Int J Radiat Oncol Biol Phys 2010, 78(1):257-267.
60. Idema A.J., Hoffmann A.L., Boogaarts H.D., et al. 3'-Deoxy-3'-18F-fluorothymidine PET-derived proliferative volume predicts overall survival in high-grade glioma patients. JNucl Med 2012, 53(12):1904-1910.
61. Jeong S.Y., Lim S.M. Comparison of 3'-deoxy-3'-[18F]fluorothymidine PET and O-(2-[18F]fluoroethyl)-L-tyrosine PET in patients with newly diagnosed glioma. Nucl Med Biol 2012, 39(7):977-981.
62. Ellingson B.M., Cloughesy T.F., Lai A., Nghiemphu P.L., Pope W.B. Cell invasion, motility, and proliferation level estimate (CIMPLE) maps derived from serial diffusion MR images in recurrent glioblastoma treated with bevacizumab. JNeurooncol 2011, 105(1):91-101.
63. O'Connor J.P., Jackson A., Parker G.J., Roberts C., Jayson G.C. Dynamic contrast-enhanced MRI in clinical trials of antivascular therapies. Nature Rev Clin Oncol 2012, 9(3):167-177.
64. Jackson A., O'Connor J.P., Parker G.J., Jayson G.C. Imaging tumor vascular heterogeneity and angiogenesis using dynamic contrast-enhanced magnetic resonance imaging. Clin Cancer Res 2007, 13(12):3449-3459.
65. Mills S.J., Patankar T.A., Haroon H.A., Baleriaux D., Swindell R., Jackson A. Do cerebral blood volume and contrast transfer coefficient predict prognosis in human glioma?. Am J Neuroradiol 2006, 27(4):853-858.
66. Patankar T.F., Haroon H.A., Mills S.J., et al. Is volume transfer coefficient (K(trans)) related to histologic grade in human gliomas?. Am J Neuroradiol 2005, 26(10):2455-2465.
67. Tsien C., Galban C.J., Chenevert T.L., et al. Parametric response map as an imaging biomarker to distinguish progression from pseudoprogression in high-grade glioma. JClin Oncol 2010, 28(13):2293-2299.
68. Galban C.J., Chenevert T.L., Meyer C.R., et al. The parametric response map is an imaging biomarker for early cancer treatment outcome. Nature Med 2009, 15(5):572-576.
69. Galban C.J., Chenevert T.L., Meyer C.R., et al. Prospective analysis of parametric response map-derived MRI biomarkers: identification of early and distinct glioma response patterns not predicted by standard radiographic assessment. Clin Cancer Res 2011, 17(14):4751-4760.
70. Chiba Y., Kinoshita M., Okita Y., et al. Use of (11)C-methionine PET parametric response map for monitoring WT1 immunotherapy response in recurrent malignant glioma. JNeurosurg 2012, 116(4):835-842.
71. Harris R.J., Cloughesy T.F., Pope W.B., et al. 18F-FDOPA and 18F-FLT positron emission tomography parametric response maps predict response in recurrent malignant gliomas treated with bevacizumab. Neuro Oncol 2012, 14(8):1079-1089.